Team

AL-S Pharma was founded in 2016 by TVM Capital Life Science and Neurimmune to develop AP-101 for the treatment of ALS

AP-101 was originally discovered using Neurimmune’s Reverse Translational Medicine platform — a clinically validated technology for generating human antibodies that target misfolded proteins implicated in neurodegenerative diseases.

Today, AL-S Pharma brings together a seasoned team of biotech and pharmaceutical leaders with expertise spanning drug discovery, translational research, and clinical development. Based on the successful Phase 2 data, the company is now advancing AP-101 into Phase 3 and preparing for late-stage development with the goal of delivering a meaningful disease-modifying therapy for ALS.

Harry Welten

Chief Executive Officer

Angela Genge, MD

Chief Medical Officer

Dirk Schimkat, lic.rer.pol

Chief Financial Officer

Bryan Boggs, Pharm.D.

Regulatory Affairs

Emma Bowden, PhD

SVP Clinical Development

Christian Somandin, PhD

CMC

Board of Directors

Hubert Birner, PhD, MBA

TVM Capital

Marc Rivière, MD

TVM Capital

Prof. Guy Rouleau, MD

Mc Gill

«I was drawn to AL-S Pharma by the scientific rigor and patient-centered mission driving the development of AP-101. Targeting misfolded SOD1 offers a promising and differentiated path in ALS, and I’m proud to help lead its clinical advancement on behalf of people living with ALS.»

Angela Genge, MD
Chief Medical Officer

«ALS remains a devastating disease with an urgent need for effective new treatment options. At AL-S Pharma, our focus is on advancing science that can translate into meaningful benefits for people living with ALS and their families. AP-101 reflects that commitment and the ambition to develop a therapy that can make a real difference in this disease.»

Harry Welten
Chief Executive Officer